Taking people in GermanyPhase 1
Tests antibodies against chronic hepatitis B in adults in a dose study
Tests antibodies against chronic hepatitis B in adults over 18.
Key facts
- Who runs it
- Region Midtjylland
- Where
- Berlin, GermanySee the siteAlso in 1 other country, 6 sites
- Trial code
- Registry title
- An ascending dose study to determine the safety and effect of antibodies against hepatitis B (The SAMBA Study)
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 48 people, planned
- Started
- 26 Aug 2024
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional
- Record updated
- 30 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic hepatitis B infection. It tests the safety and effect of antibodies against hepatitis B at rising doses.
- Age
- 18 years or older
- Sex
- All sexes can join
Main reasons for not taking part
- Healthy volunteers cannot join
Where in Germany
Also in 1 other country, 6 sites
- Charite Universitaetsmedizin Berlin KöRBerlin, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Tests antibodies against chronic hepatitis B in adults in a dose studyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 30 July 2026